

Clo-Sur P.A.D.

1

: Clo -
 Sur P.A.D.
 : 2002 8 2005 3 Clo -
 Sur P.A.D. 113 . Clo - Sur P.A.D.
 가 , 가 , , , 가 .
 92 Clo - Sur P.A.D.
 가 .
 : 113 105 (92%) 201 ,
 267
 ($p > 0.05$). 3 (2.7%), 5 (5.4%)
 , Child - Pugh class,
 ($p > 0.05$). 95% (87)가 Clo - Sur P.A.D.
 : Clo - Sur P.A.D. 가

(1).

Clo - Sur P.A.D.

, 가 ,
 1 - 5% (2). ,
 10 - 20
 6
 (3).

Clo - Sur Pressure Applied Dressing (Clo - Sur P.A.D.;
 Medtronic Vascular, Santa Rose, CA, U.S.A.) ,

2002 8 2005 3
 Clo - Sur P.A.D. 113
 가 85 , 가 28
 60 (35 - 81) 92

Clo - Sur P.A.D.

. P -value가 0.05

60 90 가 .

92 Clo - Sur P.A.D. 가 .

Clo - Sur P.A.D. (10 - 20) , , Clo - Sur P.A.D. , Clo - Sur P.A.D.

가 .

3 , 3

가

가 , 가 , 가

Child - Pugh Class, 가 , Child class , Mann - Whitney Test

113 105 . 8 (8%) 3 (2.7%) 2 30 5 (5.4%)




Fig. 1. Distribution according to the first moving time
 Note. * They followed the bed rest time for manual compression of their own free will.
 ** It took ten hours a patient to move first because of the underlying medical problem.

15 (10 - 19) . Clo - Sur P.A.D.

201 (120 - 600) , 267 (120 - 1,440) (Fig. 1).

(Table 1).

105 199 , 249 8 236 , 503 .

p -value가 0.5438, 0.0703

Child - Pugh score 가 93

Child A, 19 Child B, 1 Child C . Child - Pugh score 6.2,

Table 1. Mean Time Interval and Time Range

Patients	Total ($n=113$)		No Complication Group ($n=105$)		Complication Group ($n=8$)	
	Mean Time Interval	Time Range	Mean Time Interval	Time Range	Mean Time Interval	Time Range
From compression to first movement	201 min	120 - 600 min	199 min	120 - 600 min	236 min	150 - 480 min
From compression to walking	267 min	120 - 1440 min	249 min	120 - 1440 min	503 min	180 - 1440 min

6.0 . 4 - Angio - Seal™ (Daig, Minnetonka, MN, U.S.A.), Perclose (Perclose , Abbott Laboratory, Redwood City, CA, U.S.A.), VasoSeal (Datascope Corp., Montvale, NJ, U.S.A.), Duett™ (Vascular Solutions, Inc., Minneapolis, MN, U.S.A.)가 (14, 15).

82% . 73%, (p - value 0.0752), (p - value 0.3646), (p - value 0.6952)

143,000/μL, 132,000/μL Child - Pugh score (p - value 0.3646), (p - value 0.6952)

3 6, 155,000/μL Angio - Seal, VasoSeal, Duett, Clo - Sur P.A.D. , Syvek patch (15, 17, 18).

92 Clo - Sur P.A.D. , Femostop, Perclose (14, 19). 가 , 87 (95%) Clo - Sur Clo - Sur P.A.D. 가 . Clo - Sur P.A.D. 2001 (Food and Drug Administration, FDA) (2%) 가 3 Sur P.A.D. , , Clo - (polyprolate)

가 2 (Table 2).

1991 가 , 가 . (vascular closure device, VCD) (4 - 10). 가 1 - 5% , (11, 20 - 23). (The Quality Improvement Guidelines for Diagnostic Arteriography) (major complication) (가), (가), 가 (가), (2).

가 가 가 24 (pure collagen), + 8% (collagen + trombin), + (collagen + anchor), (vascular suture), (hemostatic patches), (pads), (staples) 1 - 5% Clo - Sur P.A.D.

Table 2. Measurement of Patients' Satisfaction

Question	Response		
Satisfaction rate with the Clo-Sur P.A.D.	Satisfaction 87 (95%)	Dissatisfaction 3* (3%)	No difference 2 (2%)
Intention to reuse the Clo-Sur P.A.D. in next TACE	Positive 84 (91%)	Negative 6** (7%)	No idea 2 (2%)
Reason for answering ' Negative or No idea ' for the above question	High-cost 5	Complication 2	No distinct difference 1

Note. * Two of them suffered re-bleeding ** Two of them suffered complications

: Clo-Sur P.A.D.
 가 (24). 가 가
 가 가 , 가
 15 가
 , Clo-Sur P.A.D. 가
 가 6 가
 19 score,
 (3, 4, 16). 가(11%), Child-Pugh class score 가(11),
 (34000/uL) 가 Clo-Sur
 P.A.D. 가 가
 가 , 가
 Clo-Sur 가
 P.A.D. 가
 Perclose 2.2 - 6.8 가
 , Angio-Seal 2.6 - 7.3 가
 1 - 3 Clo-Sur P.A.D.
 (16). 가
 가 , Perclose 288,000 , Angio-Seal 373,000
 Clo-Sur P.A.D. 71,500 , Perclose Angio-Seal
 Seal 1/5 1/4 ,
 5
 Perclose Angio-seal 가
 , Clo-Sur P.A.D. TACE
 가 Angio-seal Perclose

1. Nader RG, Garcia JC, Drushal K, Pesek T. Clinical evaluation of SyvekPatch in patients undergoing interventional, EPS and diagnostic cardiac catheterization procedures. *J Invasive Cardiol* 2002;14:305-307
2. Hoffer EK, Bloch RD. Percutaneous arterial closure devices. *J Vasc Interv Radiol* 2003;14:865-885
3. Abando A, Hood D, Weaver F, Katz S. The use of the Angioseal device for femoral artery closure. *J Vasc Surg* 2004;40:287-290
4. Sanborn TA, Gibbs HH, Brinker JA, Knopf WD, Kosinski EJ, Roubin GS. A multicenter randomized trial comparing a percutaneous collagen hemostasis device with conventional manual compression after diagnostic angiography and angioplasty. *J Am Coll Cardiol* 1993;22:1273-1279
5. Brachmann J, Ansah M, Kosinski EJ, Schuler GC. Improved clinical effectiveness with a collagen vascular hemostasis device for shortened immobilization time following diagnostic angiography and percutaneous transluminal coronary angioplasty. *Am J Cardiol* 1998;81:1502-1505
6. Pracyk JB, Wall TC, Longabaugh JP, Tice FD, Hochrein J, Green C, et al. A randomized trial of vascular hemostasis techniques to

- reduce femoral vascular complications after coronary intervention. *Am J Cardiol* 1998;81:970-976
7. Kussmaul WG 3rd, Buchbinder M, Whitlow PL, Aker UT, Heuser RR, King SB, et al. Rapid arterial hemostasis and decreased access site complications after cardiac catheterization and angioplasty: results of a randomized trial of a novel hemostatic device. *J Am Coll Cardiol* 1995;25:1685-1692
 8. Aker UT, Kensey KR, Heuser RR, Sandza JG, Kussmaul WG 3rd. Immediate arterial hemostasis after cardiac catheterization: initial experience with a new puncture closure device. *Cathet Cardiovasc Diagn* 1994;31:228-232
 9. Sesana M, Vaghetti M, Albiero R, Corvaja N, Martini G, Sivieri G, et al. Effectiveness and complications of vascular access closure devices after interventional procedures. *J Invasive Cardiol* 2000;12:395-399
 10. Baim DS, Knopf WD, Hinohara T, Schwarten DE, Schatz RA, Pinkerton CA, et al. Suture-mediated closure of the femoral access site after cardiac catheterization: results of the suture to ambulate and discharge (STAND I and STAND II) trials. *Am J Cardiol* 2000;85:864-869
 11. Meyerson SL, Feldman T, Desai TR, Leef J, Schwartz LB, McKinsey JF. Angiographic access site complications in the era of arterial closure devices. *Vasc Endovascular Surg* 2002;36:137-144
 12. Carere RG, Webb JG, Buller CE, Wilson M, Rahman T, Spinelli J, et al. Suture closure of femoral arterial puncture sites after coronary angioplasty followed by same-day discharge. *Am Heart J* 2000;139:52-58
 13. Gwechenberger M, Katzenschlager R, Heinz G, Gottsauner-Wolf M, Probst P. Use of a collagen plug versus manual compression for sealing arterial puncture site after cardiac catheterization. *Angiology* 1997;48:121-126
 14. Amin FR, Yousufuddin M, Stables R, Shamim W, Al-Nasser F, Coats AJ, et al. Femoral haemostasis after transcatheter therapeutic intervention: a prospective randomised study of the angio-seal device versus the femostop device. *Int J Cardiol* 2000;76:235-240
 15. Gershony G, Jensen T. The Duett closure device: concept and experimental results. *Herz* 1999;24:614-619
 16. Lasic Z, Nikolsky E, Kesanakurthy S, Dangas G. Vascular closure devices: a review of their use after invasive procedures. *Am J Cardiovasc Drugs* 2005;5:185-200
 17. Hong K, Liapi E, Georgiades CS, Geschwind JF. Case-controlled comparison of a percutaneous collagen arteriotomy closure device versus manual compression after liver chemoembolization. *J Vasc Interv Radiol* 2005;16:339-345
 18. Foran JP, Patel D, Brookes J, Wainwright RJ. Early mobilisation after percutaneous cardiac catheterisation using collagen plug (VasoSeal) haemostasis. *Br Heart J* 1993;69:424-429
 19. Vaitkus PT. A meta-analysis of percutaneous vascular closure devices after diagnostic catheterization and percutaneous coronary intervention. *J Invasive Cardiol* 2004;16:243-246
 20. Koreny M, Riedmuller E, Nikfardjam M, Siostrzonek P, Mullner M. Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: systematic review and meta-analysis. *JAMA* 2004;291:350-357
 21. Sanborn TA, Gibbs HH, Brinker JA, Knopf WD, Kosinski EJ, Roubin GS. A multicenter randomized trial comparing a percutaneous collagen hemostasis device with conventional manual compression after diagnostic angiography and angioplasty. *J Am Coll Cardiol* 1993;22:1273-1279
 22. Silber S. Hemostasis success rates and local complications with collagen after femoral access for cardiac catheterization: analysis of 6007 published patients. *Am Heart J* 1998;135:152-156
 23. Webb JG, Carere RA, Dodek AA. Collagen plug hemostatic closure of femoral arterial puncture sites following implantation of intracoronary stents. *Cathet Cardiovasc Diagn* 1993;30:314-316
 24. Mlekusch W, Dick P, Haumer M, Sabeti S, Minar E, Schillinger M. Arterial puncture site management after percutaneous transluminal procedures using a hemostatic wound dressing (Clo-Sur P.A.D.) versus conventional manual compression: a randomized controlled trial. *J Endovasc Ther* 2006;13:23-31

The Safety and Efficacy of Hemostasis with Clo-Sur P.A.D. after Transcatheter Arterial Chemoembolization¹

Seung Chai Jung, M.D., Hwan Jun Jae, M.D., Sang Youn Kim, M.D.,
Whal Lee, M.D., Jin Wook Chung, M.D., Jae Hyung Park, M.D.

¹Department of Radiology, Seoul National University College of Medicine,
Institute of Radiation Medicine, Seoul National University Medical Research Center,
and Clinical Research Institute, Seoul National University Hospital

Purpose: We wanted to evaluate the safety and efficacy of a new hemostatic device, Clo-Sur P.A.D., at an arterial access site after performing femoral arterial catheterization to achieve transcatheter arterial chemoembolization (TACE).

Materials and Methods: From August 2002 to March 2005, 113 patients who underwent TACE and agreed on using the Clo-Sur P.A.D. were enrolled in this study. We evaluated the mean time interval from compression to the first movement and also to the first walk. We also evaluated such complications as rebleeding, pseudoaneurysm, vascular occlusion, hematoma, infection and pain. For 92 patients who had previous experiences with manual compression, we evaluated their preference of hemostatic method by asking them.

Results: Successful hemostasis was achieved with the Clo-Sur P.A.D. in 105 subjects (92%). The mean time interval from compression to the first movement was 201 minutes, and that to the first walk was 267 minutes. There was no statistical difference between the complicated and the uncomplicated groups for the mean time, prothrombin time, Child-Pugh class and platelet count ($p > 0.05$). Rebleeding occurred in 3 patients (2.7%) and mild hematoma around puncture site was noted in 5 patients (5.4%). Eighty-seven patients (95%) preferred Clo-Sur P.A.D. to the manual compression method.

Conclusion: The Clo-Sur P.A.D. is a safe and effective hemostatic device and it provides early ambulation after TACE.

Index words : Arteries, femoral
Arteries, interventional procedures
Catheters and catheterization, complications
Hepatic arteries, chemotherapeutic embolization

Address reprint requests to : Hwan Jun Jae, M.D., Department of Radiology, Seoul National University College of Medicine
28, Yongon-dong, Chongno-gu, Seoul 110-744, Korea
Tel. 82-2-2072-1737 Fax. 82-2-743-6385 E-mail: jhj@radiol.snu.ac.kr